---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-26-001150"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:18.912134+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q4/FY2025: Revenue $37.1M (+4% YoY), net loss improves to $8.2M; targets H2 2026 cash breakeven

## Summary
- Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
- Adjusted net loss $14.2M ($0.23/sh) flat per share; adjusted EBITDA loss $10.5M improved from $11.5M.
- Cash $7.8M at Dec 31, 2025; amended credit facility added $2.5M; workforce reduced 10% in Q4.
- Targets cash flow breakeven in H2 2026; ongoing FDA discussions for DrugSorb-ATR De Novo submission (timing TBD).
- Direct sales outside Germany +13%, distributor sales +11.4%; Germany sales -10% due to restructuring.

## SEC filing metadata
- accession: 0000929638-26-001150
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001150/0000929638-26-001150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001150/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-26-001150
- JSON: https://secwatch.observer/filing/0000929638-26-001150.json
- Plain text: https://secwatch.observer/filing/0000929638-26-001150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.